Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

Abstract In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non‐small‐cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether...

Full description

Saved in:
Bibliographic Details
Main Authors: Apar Pataer, Ruping Shao, Arlene M. Correa, Carmen Behrens, Jack A. Roth, Ara A. Vaporciyan, Ignacio I. Wistuba, Stephen G. Swisher
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Cancer Medicine
Subjects:
Biomarker
lung cancer
neoadjuvant chemotherapy
RAD51
Online Access:https://doi.org/10.1002/cam4.1505
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.1505

Similar Items